Publications

Detailed Information

Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea

DC Field Value Language
dc.contributor.authorChoi, Kee Don-
dc.contributor.authorKim, Nayoung-
dc.contributor.authorJang, In-Jin-
dc.contributor.authorPark, Young Soo-
dc.contributor.authorKim, Jung-Ryul-
dc.contributor.authorJung, Hyun Chae-
dc.contributor.authorSong, In Sung-
dc.contributor.authorShin, Jai Moo-
dc.contributor.authorCho, Joo Youn-
dc.date.accessioned2012-05-24T07:13:20Z-
dc.date.available2012-05-24T07:13:20Z-
dc.date.issued2009-10-
dc.identifier.citationJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY; Vol.24 10; 1617-1624ko_KR
dc.identifier.issn0815-9319-
dc.identifier.urihttps://hdl.handle.net/10371/76436-
dc.description.abstractBackground and Aim: The lowest effective dose of proton pump inhibitors (PPI) for prevention of peptic ulcer rebleeding remains unclear. The objective of the present study was to evaluate whether low-dose PPI has a similar efficacy to high-dose i.v. administration for maintaining intragastric pH above 6. Methods: Sixty-one patients with bleeding ulcers were randomized into one of three groups after endoscopic hemostasis: pantoprazole 80 mg bolus followed by 8 mg/h; 40 mg, 4 mg/h infusion; and bolus injection of 40 mg every 24 h. Intragastric pH values and rebleeding rates were measured. In addition, pharmacokinetic parameters and association with CYP2C19 polymorphisms and H. pylori infection were assessed. Results: Mean percentage of time with intragastric pH > 6, and the proportion of patients with pH > 6 for more than 60% of the time were significantly higher in the 40 mg, 4 mg/h infusion group compared to the 40 mg bolus injection. There was no significant difference between the 80 mg, 8 mg/h and the 40 mg, 4 mg/h groups. In the H. pylori (-) group, only 40% of patients that received continuous infusion reached the target pH > 6 for more than 60% of the time; this was significantly lower than the H. pylori (+) group, 87.5% (P = 0.026). Conclusions: A continuous infusion, regardless of high or low dose, was more effective for acid suppression than a 40 mg bolus PPI injection in Korea. H. pylori infection was an important factor for the maintenance of an intragastric pH > 6.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.subjectCYP2C19ko_KR
dc.subjectHelicobacter pyloriko_KR
dc.subjectproton pump inhibitorko_KR
dc.subjectpeptic ulcer bleedingko_KR
dc.subjectintravenous infusionsko_KR
dc.titleOptimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Koreako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor최기돈-
dc.contributor.AlternativeAuthor김나영-
dc.contributor.AlternativeAuthor장인진-
dc.contributor.AlternativeAuthor박영수-
dc.contributor.AlternativeAuthor조주윤-
dc.contributor.AlternativeAuthor김정렬-
dc.contributor.AlternativeAuthor신재무-
dc.contributor.AlternativeAuthor정현채-
dc.contributor.AlternativeAuthor송인성-
dc.identifier.doi10.1111/j.1440-1746.2009.05939.x-
dc.citation.journaltitleJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY-
dc.description.citedreferenceKim N, 2008, HELICOBACTER, V13, P245, DOI 10.1111/j.1523-5378.2008.00604.x-
dc.description.citedreferenceKang JM, 2008, J GASTROEN HEPATOL, V23, P1287, DOI 10.1111/j.1440-1746.2008.05392.x-
dc.description.citedreferenceNaylor GM, 2006, GUT, V55, P1545, DOI 10.1136/gut.2005.080358-
dc.description.citedreferenceLim PWY, 2005, J GASTROEN HEPATOL, V20, pS22, DOI 10.1111/j.1440-1746.2005.0416-7.x-
dc.description.citedreferenceLeontiadis GI, 2005, ALIMENT PHARM THERAP, V21, P1055, DOI 10.1111/j.1365-2036.2005.02441.x-
dc.description.citedreferenceBardou M, 2005, ALIMENT PHARM THERAP, V21, P677, DOI 10.1111/j.1365-2036.2005.02391.x-
dc.description.citedreferenceAndriulli A, 2005, AM J GASTROENTEROL, V100, P207, DOI 10.1111/j.1572-0241.2005.40636.x-
dc.description.citedreferenceFURUTA T, 2005, DRUG METAB PHARMACOK, V20, P153-
dc.description.citedreferenceSugimoto M, 2004, CLIN PHARMACOL THER, V76, P290, DOI 10.1016/j.clpt.2004.06.008-
dc.description.citedreferenceYu KS, 2004, J CLIN PHARMACOL, V44, P73, DOI 10.1177/0091270003261321-
dc.description.citedreferencevan Rensburg CJ, 2003, AM J GASTROENTEROL, V98, P2635, DOI 10.1016/j.amjgastroenterol.2003.08.025-
dc.description.citedreferenceBarkun A, 2003, ANN INTERN MED, V139, P843-
dc.description.citedreferenceSaitoh T, 2002, ALIMENT PHARM THERAP, V16, P1811, DOI 10.1046/j.0269-2813.2002.01348.x-
dc.description.citedreferenceUdd M, 2001, SCAND J GASTROENTERO, V36, P1332-
dc.description.citedreferenceFuruta T, 2001, CLIN PHARMACOL THER, V70, P484, DOI 10.1067/mcp.2001.119721-
dc.description.citedreferenceHorai Y, 2001, ALIMENT PHARM THERAP, V15, P793-
dc.description.citedreferenceFuruta T, 1999, CLIN PHARMACOL THER, V65, P552-
dc.description.citedreferenceHaruma K, 1999, ALIMENT PHARM THERAP, V13, P155-
dc.description.citedreferenceHan KS, 1997, J CHROMATOGR B, V696, P312-
dc.description.citedreferenceKubota T, 1996, CLIN PHARMACOL THER, V60, P661-
dc.description.citedreferenceCaraco Y, 1996, CLIN PHARMACOL THER, V60, P157-
dc.description.citedreferenceBrunner G, 1996, YALE J BIOL MED, V69, P225-
dc.description.citedreferenceRockall TA, 1996, GUT, V38, P316-
dc.description.citedreferenceVERDU EF, 1995, GUT, V36, P539-
dc.description.citedreferenceDEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594-
dc.description.citedreferenceBEIL W, 1994, GUT, V35, P1176-
dc.description.citedreferenceDEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419-
dc.description.citedreferenceNOACH LA, 1994, SCAND J GASTROENTERO, V29, P425-
dc.description.citedreferenceWALLACE JL, 1991, AM J PHYSIOL, V261, pG559-
dc.description.citedreferencePATCHETT SE, 1989, GUT, V30, P1704-
dc.description.citedreferenceLAM SK, 1980, GUT, V21, P324-
dc.description.citedreferenceGREEN FW, 1978, GASTROENTEROLOGY, V74, P38-
dc.description.tc2-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share